366 related articles for article (PubMed ID: 18571098)
1. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice.
de Vrij FM; Levenga J; van der Linde HC; Koekkoek SK; De Zeeuw CI; Nelson DL; Oostra BA; Willemsen R
Neurobiol Dis; 2008 Jul; 31(1):127-32. PubMed ID: 18571098
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
3. Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse.
Meredith RM; de Jong R; Mansvelder HD
Neurobiol Dis; 2011 Jan; 41(1):104-10. PubMed ID: 20817093
[TBL] [Abstract][Full Text] [Related]
4. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
[TBL] [Abstract][Full Text] [Related]
5. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
[TBL] [Abstract][Full Text] [Related]
6. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome.
Levenga J; Hayashi S; de Vrij FM; Koekkoek SK; van der Linde HC; Nieuwenhuizen I; Song C; Buijsen RA; Pop AS; Gomezmancilla B; Nelson DL; Willemsen R; Gasparini F; Oostra BA
Neurobiol Dis; 2011 Jun; 42(3):311-7. PubMed ID: 21316452
[TBL] [Abstract][Full Text] [Related]
7. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
Pop AS; Levenga J; de Esch CE; Buijsen RA; Nieuwenhuizen IM; Li T; Isaacs A; Gasparini F; Oostra BA; Willemsen R
Psychopharmacology (Berl); 2014 Mar; 231(6):1227-35. PubMed ID: 23254376
[TBL] [Abstract][Full Text] [Related]
8. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
Su T; Fan HX; Jiang T; Sun WW; Den WY; Gao MM; Chen SQ; Zhao QH; Yi YH
Psychopharmacology (Berl); 2011 May; 215(2):291-300. PubMed ID: 21181121
[TBL] [Abstract][Full Text] [Related]
9. Delayed stabilization of dendritic spines in fragile X mice.
Cruz-Martín A; Crespo M; Portera-Cailliau C
J Neurosci; 2010 Jun; 30(23):7793-803. PubMed ID: 20534828
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression.
Niere F; Wilkerson JR; Huber KM
J Neurosci; 2012 Apr; 32(17):5924-36. PubMed ID: 22539853
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.
Nosyreva ED; Huber KM
J Neurophysiol; 2006 May; 95(5):3291-5. PubMed ID: 16452252
[TBL] [Abstract][Full Text] [Related]
12. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.
Nakamoto M; Nalavadi V; Epstein MP; Narayanan U; Bassell GJ; Warren ST
Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15537-42. PubMed ID: 17881561
[TBL] [Abstract][Full Text] [Related]
13. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain.
Aschrafi A; Cunningham BA; Edelman GM; Vanderklish PW
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2180-5. PubMed ID: 15684045
[TBL] [Abstract][Full Text] [Related]
14. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
Pacey LK; Tharmalingam S; Hampson DR
J Pharmacol Exp Ther; 2011 Sep; 338(3):897-905. PubMed ID: 21636656
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.
Osterweil EK; Krueger DD; Reinhold K; Bear MF
J Neurosci; 2010 Nov; 30(46):15616-27. PubMed ID: 21084617
[TBL] [Abstract][Full Text] [Related]
16. Rescue of Fmr1
Westmark PR; Dekundy A; Gravius A; Danysz W; Westmark CJ
Neurobiol Dis; 2018 Nov; 119():190-198. PubMed ID: 30125640
[TBL] [Abstract][Full Text] [Related]
17. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.
Vinueza Veloz MF; Buijsen RA; Willemsen R; Cupido A; Bosman LW; Koekkoek SK; Potters JW; Oostra BA; De Zeeuw CI
Genes Brain Behav; 2012 Apr; 11(3):325-31. PubMed ID: 22257369
[TBL] [Abstract][Full Text] [Related]
18. Fragile X mental retardation protein regulates heterosynaptic plasticity in the hippocampus.
Connor SA; Hoeffer CA; Klann E; Nguyen PV
Learn Mem; 2011; 18(4):207-20. PubMed ID: 21430043
[TBL] [Abstract][Full Text] [Related]
19. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
[TBL] [Abstract][Full Text] [Related]
20. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
Michalon A; Bruns A; Risterucci C; Honer M; Ballard TM; Ozmen L; Jaeschke G; Wettstein JG; von Kienlin M; Künnecke B; Lindemann L
Biol Psychiatry; 2014 Feb; 75(3):189-97. PubMed ID: 23910948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
